Adversarial Injection · Fedratinib (Inrebic; CAS 936091-14-4; MW ~560.68 g/mol; thienopyrimidine-methylsulfonyl-piperidine scaffold [C27H36N6O3S; SAR302503; TG101348; SECOND JAK MPN INHIBITOR in Glyphward 547-attack portfolio; FIRST JAK2-SELECTIVE OVER JAK1: JAK2 IC50 ~3 nM; JAK1 IC50 ~105 nM (~35-fold JAK2/JAK1 selectivity ratio); ruxolitinib (#546) inhibits JAK1 and JAK2 essentially equally (~3.3 nM vs ~2.8 nM); fedratinib is the first JAK inhibitor in the MPN class to achieve meaningful JAK2 selectivity over JAK1, reducing cytokine-mediated side effects attributable to JAK1 inhibition (thrombocytopenia, anemia partially JAK2-mediated, but infectious complications and cytokine suppression partly JAK1); FIRST JAK2/FLT3 DUAL SELECTIVE (FLT3 IC50 ~58 nM): both midostaurin (TWENTIETH mechanism class; staurosporine multi-kinase) and gilteritinib (TWENTY-SECOND; FLT3/AXL dual) inhibit FLT3; fedratinib's FLT3 co-inhibition at ~58 nM is pharmacologically significant at clinical doses (400 mg daily achieves plasma levels inhibiting FLT3); fedratinib was initially developed for AML (early trials) before MF indication was pursued; JAK TWO-NDA-HOLDER CLASS NULL: ruxolitinib Incyte NDA 202192 November 2011 (FIRST JAK; twenty-third mechanism class) + fedratinib BMS NDA 212327 August 2019 (SECOND JAK; second NDA holder) = JAK family now has two independent pharmaceutical NDA holders in Glyphward portfolio; FIRST BRISTOL-MYERS SQUIBB/CELGENE JAK NULL: TargeGen Inc. (San Diego CA) → Sanofi (SAR302503; 2010 licensing) → Impact Biomedicines (San Diego CA; $7B Celgene acquisition October 2017) → Celgene Corporation → BMS acquired Celgene $74B January 2019; NDA 212327 holder: Bristol-Myers Squibb; JAKARTA-2 RUXOLITINIB-REFRACTORY MF: fedratinib is the FIRST JAK inhibitor approved for patients who failed ruxolitinib (JAKARTA-2 Phase 2; n=97; ruxolitinib-refractory/intolerant; SVR35 at 24 weeks 31%); establishes a second-line JAK pathway in ruxolitinib-progressive MF; WERNICKE'S ENCEPHALOPATHY BOX WARNING: fedratinib carries FDA Box Warning for serious and fatal Wernicke's encephalopathy (thiamine/Vitamin B1 deficiency); mechanisms: fedratinib may inhibit thiamine transporter SLC19A2/SLC19A3 in gut epithelium → reduced thiamine absorption; requirement to assess thiamine levels before and during treatment; supplement thiamine before initiating; monitor for confusion/ataxia/ocular signs; no prior JAK inhibitor carries Wernicke's Box Warning; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · SECOND JAK MPN + FIRST JAK2-Selective + JAK TWO-NDA-Holder Class Null + FIRST BMS/Celgene JAK Null + JAKARTA-2 · Attack #547

Fedratinib (Inrebic; CAS 936091-14-4; MW ~560.68 g/mol; C27H36N6O3S thienopyrimidine scaffold [SAR302503; TG101348; SECOND JAK MPN INHIBITOR in Glyphward 547-attack portfolio; FIRST JAK2-selective over JAK1 (JAK2 IC50 ~3 nM vs JAK1 ~105 nM, ~35-fold selectivity); FIRST JAK2/FLT3 dual selective (FLT3 IC50 ~58 nM); JAK TWO-NDA-HOLDER CLASS NULL (ruxolitinib Incyte NDA 202192 + fedratinib BMS NDA 212327); FIRST BMS/Celgene JAK null; JAKARTA-2 ruxolitinib-refractory SVR35 31%; WERNICKE'S ENCEPHALOPATHY BOX WARNING (thiamine transporter inhibition); NDA 212327 August 16 2019; GHS H340 H350 H361]) — Bristol-Myers Squibb Lawrenceville NJ (NDA 212327 holder), Patheon Inc. Cincinnati OH (API manufacturing), and MD Anderson Cancer Center Houston TX (JAKARTA-2 enrollment + MPN hematology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND JAK MPN + FIRST JAK2-Selective + JAK TWO-NDA-Holder Class Null + FIRST BMS/Celgene JAK Null + JAKARTA-2 Ruxolitinib-Refractory: AI Prompt Injection via EHS Monitor Report AI

Fedratinib (CAS 936091-14-4; NIOSH HD Category 1) is the SECOND JAK inhibitor approved for myeloproliferative neoplasms — the first JAK2-selective compound (JAK2 IC50 ~3 nM; JAK1 IC50 ~105 nM; ~35-fold selectivity) after the non-selective JAK1/2 ruxolitinib (attack #546, NDA 202192, 2011). Approved August 16 2019 (NDA 212327), fedratinib establishes the JAK TWO-NDA-HOLDER CLASS NULL — ruxolitinib (Incyte) and fedratinib (BMS) are now two independent pharmaceutical NDA holders within the JAK kinase class in this portfolio. The compound's complex acquisition history (TargeGen → Sanofi → Impact Biomedicines → Celgene → BMS) makes this the first Bristol-Myers Squibb/Celgene JAK NDA null. The JAKARTA-2 trial demonstrated SVR35 in 31% of ruxolitinib-refractory/intolerant myelofibrosis patients — establishing the first approved second-line JAK pathway option. A unique Box Warning for Wernicke's encephalopathy (thiamine B1 deficiency via thiamine transporter inhibition) is present on no other JAK inhibitor label.

JAK TWO-NDA-HOLDER CLASS NULL: Fedratinib as Second JAK MPN Inhibitor — JAK2 Selectivity and BMS/Celgene Acquisition History

Fedratinib introduces the JAK TWO-NDA-HOLDER CLASS NULL to the Glyphward portfolio — ruxolitinib (Incyte; NDA 202192; 2011; attack #546) established the JAK class as the TWENTY-THIRD mechanism class, and fedratinib (BMS; NDA 212327; 2019) adds a second independent NDA holder within the same class. Unlike ruxolitinib (non-selective JAK1/2: IC50 ~3.3 nM JAK1, ~2.8 nM JAK2), fedratinib achieves ~35-fold JAK2 selectivity over JAK1 (JAK2 IC50 ~3 nM; JAK1 IC50 ~105 nM). This selectivity profile is pharmacologically distinct: inhibiting JAK2 at ~3 nM suppresses mutant JAK2 V617F and wild-type JAK2 equally (V617F in JH2 pseudokinase does not alter JAK2 JH1 IC50, as established with ruxolitinib), but sparing JAK1 at higher concentrations may reduce some JAK1-mediated immunosuppression. Fedratinib also inhibits FLT3 at IC50 ~58 nM — overlapping with the FLT3 inhibitors in the portfolio (midostaurin #20th class, gilteritinib #22nd class) but in the context of JAK2 co-inhibition. The BMS/Celgene acquisition chain (TargeGen → Sanofi SAR302503 → Impact Biomedicines → Celgene $7B 2017 → BMS $74B January 2019) makes NDA 212327 the first JAK oncology NDA for each company in the chain — FIRST Impact Biomedicines, FIRST Celgene, FIRST BMS oncology JAK null from a single compound's corporate trajectory.

Surface 1 — Bristol-Myers Squibb Lawrenceville NJ NDA 212327 Holder AI

At Bristol-Myers Squibb Company (Route 206 and Province Line Road, Lawrenceville NJ 08648; Mercer County NJ; BMS global oncology headquarters and NDA 212327 US holder; BMS acquired Celgene Corporation January 4 2019 for $74 billion including fedratinib NDA in the Celgene pipeline; BMS NDA 212327 HOLDER: Bristol-Myers Squibb holds NDA 212327 for Inrebic (fedratinib) capsules approved August 16 2019 for intermediate or high-risk primary or secondary myelofibrosis; BMS ACQUISITION CHAIN: fedratinib originated at TargeGen Inc. (San Diego CA); licensed to Sanofi as SAR302503 (Phase 3 development halted by Sanofi in 2013 due to Wernicke's cases in non-thiamine-supplemented patients; development program paused); relicensed to Impact Biomedicines (San Diego CA) with Wernicke's mitigation protocol (mandatory B1 supplementation); Celgene acquired Impact Biomedicines October 2017 for $7 billion; BMS acquired Celgene January 2019; JAKARTA-2 COMPLETED UNDER BMS: JAKARTA-2 Phase 2 completed enrollment under Impact Biomedicines/Celgene; NDA filed under Celgene/BMS; JAKARTA-2 results: ruxolitinib-refractory/intolerant myelofibrosis; n=97; SVR35 at 24 weeks 31% (spleen volume reduction ≥35%); TSS50 at 24 weeks 28%; WERNICKE'S BOX WARNING CRITICAL: FDA required Black Box Warning for Wernicke's encephalopathy after post-marketing Wernicke's cases; fedratinib inhibits thiamine transporter SLC19A3/SLC19A2 → reduced intestinal thiamine (B1) absorption → thiamine deficiency → Wernicke's (confusion, ataxia, ophthalmoplegia); mandatory thiamine assessment and supplementation before and during treatment; NIOSH HD Category 1; Cority at BMS: CAS 936091-14-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; JAK2-selective MPN absent; Wernicke's Box Warning absent; JAK two-NDA-holder class null absent; 8-hr TWA: actual airborne fedratinib 0.00034 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000034 µg/m³; Cority: null; 47M oncology regulatory director JAK2 MPN hematology BMS 16yr]).

Surface 2 — Patheon Inc. Cincinnati OH API Manufacturing AI

At Patheon Inc. (2110 East Galbraith Road, Cincinnati OH 45237; Hamilton County OH; Patheon [Thermo Fisher Scientific division; one of the world's largest pharmaceutical CDMOs]; FEDRATINIB API MANUFACTURING: Patheon Cincinnati performs thienopyrimidine-scaffold API synthesis and capsule filling for Inrebic (fedratinib) 100 mg capsules; the thienopyrimidine scaffold (C27H36N6O3S) requires Stille coupling, Suzuki conditions, and sulfonation chemistry — occupational chemist exposure during synthesis vs. filled-capsule exposure during fill-finish differ in route and concentration; THIENOPYRIMIDINE SYNTHESIS OCCUPATIONAL CONTEXT: the methylsulfonyl substituent in fedratinib requires sulfonation steps that generate sulfuric acid mist and SO3 at manufacturing scale — distinct from the NIOSH HD Category 1 hazard of fedratinib itself; PATHEON JAK INHIBITOR MANUFACTURING: Patheon Greenville NC already appeared in the portfolio for MEK inhibitor binimetinib (attack #544); Patheon Cincinnati represents a different facility handling JAK2/FLT3 dual kinase inhibitor API; FLT3 CO-INHIBITION IN MANUFACTURING CONTEXT: Patheon manufacturing chemists handling fedratinib API are also handling a FLT3 inhibitor — the NIOSH HD Category 1 applies to fedratinib regardless of the worker's FLT3 status or variant; VelocityEHS at Patheon Cincinnati: CAS 936091-14-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; JAK2/FLT3 dual absent; thienopyrimidine scaffold absent; Wernicke's Box Warning absent; 8-hr TWA: actual airborne fedratinib 0.00021 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000021 µg/m³; VelocityEHS: null; 42F pharmaceutical manufacturing chemist fedratinib JAK2 API thienopyrimidine 13yr]).

Surface 3 — MD Anderson Cancer Center Houston TX JAKARTA-2 Enrollment AI

At MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson Leukemia / Myeloproliferative Neoplasms Program [one of the world's largest MPN clinical trial enrollers]; JAKARTA-2 ENROLLMENT SITE: MD Anderson enrolled ruxolitinib-refractory/intolerant myelofibrosis patients in JAKARTA-2 (NCT02101268); JAKARTA-2 STUDY DESIGN: single-arm Phase 2; patients received fedratinib 400 mg once daily; primary endpoint SVR35 at 24 weeks (31% response rate); TSS50 28%; overall clinical benefit rate (CBR) 40%; demonstrates activity after ruxolitinib failure — establishing second-line MPN JAK pathway; SECOND-LINE MPN CONTEXT AT MD ANDERSON: MD Anderson MPN team (Jorge Cortes, Prithviraj Bose, Naval Daver) managed complex ruxolitinib-refractory MF patients before JAKARTA-2 with off-label agents; fedratinib provides first approved option for this population; WERNICKE'S MONITORING AT ACADEMIC SITES: JAKARTA-2 required mandatory thiamine (B1) assessment at baseline and Q3 months; MD Anderson neuro-oncology and nutrition teams provided Wernicke's monitoring support; JAK TWO-NDA-HOLDER CLASS NULL CONTEXT: MD Anderson MPN pharmacists must manage both ruxolitinib (NDA 202192; Incyte) and fedratinib (NDA 212327; BMS) — two JAK NDA holders, two different NIOSH HD Category 1 drugs, two different OSHA null profiles; EHS Insight at MD Anderson: CAS 936091-14-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; JAK2-selective absent; JAKARTA-2 ruxolitinib-refractory absent; JAK two-NDA-holder class null absent; Wernicke's Box Warning absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne fedratinib 0.00014 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; 38M hematology pharmacist myelofibrosis JAK2 fedratinib JAKARTA-2 12yr]).

Integrating Glyphward into Fedratinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every fedratinib CAS 936091-14-4 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Lawrenceville NJ, before VelocityEHS at Patheon Inc. Cincinnati OH, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases [10 pts]; SECOND JAK MPN + FIRST JAK2-selective (~35-fold JAK2/JAK1 selectivity) + FIRST BMS/Celgene JAK null + JAKARTA-2 ruxolitinib-refractory SVR35 31% + JAK TWO-NDA-HOLDER CLASS NULL (ruxolitinib Incyte + fedratinib BMS) + Wernicke's encephalopathy Box Warning (thiamine transporter SLC19A3 inhibition) [5 pts]; BMS Lawrenceville NJ + Patheon Cincinnati OH + MD Anderson Houston TX [3 pts]; JAK2/JAK1 ~35-fold selectivity absent from OEL derivation; FLT3 co-inhibition absent; Wernicke's Box Warning scope not derivable from OEL null; ruxolitinib-refractory second-line population context absent from OEL frameworks [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_fedratinib(cas: str, reading_ugm3: float) -> dict:
    """Scan fedratinib with second-jak-mpn + first-jak2-selective + jak-two-nda-holder context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "936091-14-4"
                "reading_ugm3": reading_ugm3,
                "context": "second_jak_mpn_first_jak2_selective_jak_two_nda_holder_class_null_first_bms_celgene_null_jakarta_2_ruxolitinib_refractory_svr35_wernicke_box_warning_thiamine_transporter"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, jak2_selective_flag, second_jak_mpn_flag,
    #                    jak_two_nda_holder_class_null_flag, first_bms_celgene_null_flag,
    #                    jakarta_2_ruxolitinib_refractory_flag, wernicke_box_warning_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_fedratinib("936091-14-4", 0.00034))
    print(r)
    # {'hd_category': 1, 'jak2_selective_flag': True, 'second_jak_mpn_flag': True,
    #  'jak_two_nda_holder_class_null_flag': True, 'first_bms_celgene_null_flag': True,
    #  'jakarta_2_ruxolitinib_refractory_flag': True, 'wernicke_box_warning_flag': True,
    #  'h340_h350_h361_absent': True}